(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
7 Extraordinary Efficiency Applications for Experts - 2Peloton recalls more than 800,000 bikes after broken seat posts injure users
- 3The Job of a Migration Legal advisor: How They Can Help You
- 4Archaeologists uncover details about the Hjortspring boat's origins
- 5Denny's is shutting down restaurants around the country. What's behind the closures?
- Council removes proposal to rename park named after former president of Israel
- Timothy Busfield turns himself in to face child sexual abuse charges in New Mexico
- Cathay Pacific raises fuel surcharge on all flights by 34%
- Famous Places to get-away for Americans
- Find the Abilities Required for Advanced Advertising Position
- Novo Nordisk cuts Wegovy price as CEO pledges to go 'all in' on weight loss pill
- The Ascent of Rousing Pioneers Who Formed History
- Lucky airplane passengers capture NASA's Artemis 2 moon launch from the sky
- Zelensky warns of imminent massive Russian attack on Ukraine
